| Chemical Name | 3-Quinuclidinone Hydrochloride |
| Synonyms | 3-Quinuclidone HCl; Quinuclidin-3-one Hydrochloride |
| CAS Number | 1193-65-3 |
| CAT Number | RF-PI154 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C7H12ClNO |
| Molecular Weight | 161.63 |
| Melting Point | 300℃ (dec.) |
| Condition to Avoid | Hygroscopic |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White to Off-White Crystalline Powder |
| Identification IR Spectrum | Conforms to Reference Spectrum |
| Loss on Drying | ≤0.50% |
| Residue on Ignition | ≤0.30% |
| Assay | 98.0%~102.0% (TLC) |
| Test Standard | Enterprise Standard |
| Usage | Pharmaceutical Intermediates |
Package: Bottle, Aluminium foil bag, Cardboard Drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Manufacturer with High Quality and Competitive Price
Commercial Supply Solifenacin Succinate (CAS: 242478-38-2) Related Intermediates:
Solifenacin Succinate CAS: 242478-38-2
(R)-(-)-3-Quinuclidinol CAS: 25333-42-0
(S)-(+)-3-Quinuclidinol CAS: 34583-34-1
3-Quinuclidinone Hydrochloride CAS: 1193-65-3
(R)-3-Quinuclidinol hydrochloride CAS: 42437-96-7
1-Phenyl-1,2,3,4-tetrahydro-isoquinoline CAS: 22990-19-8
(S)-1-Phenyl-1,2,3,4-tetrahydroisoquinoline CAS: 118864-75-8
Solifenacin Succinate (CAS: 242478-38-2) is an antimuscarinic medication that is used to treat an overactive bladder causing symptoms of frequency, urgency, or incontinence.
Solifenacin Succinate (CAS: 242478-38-2) is an M3 muscarinic receptor antagonist that was developed and launched for the treatment of overactive bladder (pollakiuria) in Europe. M3 receptors have been implicated in neurally evoked smooth muscle contractions of the bladder, and M2 receptors have also been suspected of playing a role because of their dominance in the detrusor muscle. Solifenacin displays affinity for both M3 and M2 receptors with Ki values of 9.9nM and 120 nM, respectively. Since muscarinic salivary glands are of the M3 persuasion, a common side effect of antimuscarinic therapy is dry mouth. At the cellular level, solifenacin possesses a selective preference for bladder over salivary gland that is 15-fold greater than that of atropine suggesting a lower probability of inducing dry mouth at pharmacologically relevant doses. The synthesis of solifenacin involves the preparation of racemic 1-phenyl- 1,2,3,4-tetrahydroisoquinoline via cyclization of N-(2-phenylethyl)benzamide, and subsequent reaction with ethyl chloroformate and transesterification with (R)- 3-quinuclidinol. Chiral chromatography affords the isolation of the desired diastereomer. Alternatively, 1-phenyl-1,2,3,4-tetrahydroisoquinoline may be subjected to optical resolution with (+)-tartaric acid prior to treatment with ethyl chloroformate and subsequent transesterification.